Benzimidazole
Based on 1 Customer Validation
Benzimidazole is a biochemical reagent that can be used as a biological material or organic compound for life science related research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.92%
- CAS 番号: 51-17-2
- 分子式: C7H6N2
- 分子量:118.14
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Parasite アイソフォーム固有の製品をすべて表示
More
生物活性
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
>100 μM
Compound: TBZ, Thiabendazole
|
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation rate after 72 hrs by MTT assay
Cytotoxicity against human A549 cells assessed as inhibition of cell proliferation rate after 72 hrs by MTT assay
|
[PMID: 25936258] |
| A549 | IC50 |
>20 μM
Compound: Benzimidazole
|
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 30822712] |
| CHO | IC50 |
>100 μM
Compound: 9
|
Inhibition of human VAP-1 expressed in CHO cells using [14C]-benzylamine as substrate preincubated for 30 mins prior to substrate addition measured after 1 hr by scintillation spectrometric analysis
Inhibition of human VAP-1 expressed in CHO cells using [14C]-benzylamine as substrate preincubated for 30 mins prior to substrate addition measured after 1 hr by scintillation spectrometric analysis
|
[PMID: 23664164] |
| CHO | IC50 |
>100 μM
Compound: 9
|
Inhibition of rat VAP-1 expressed in CHO cells using [14C]-benzylamine as substrate preincubated for 30 mins prior to substrate addition measured after 1 hr by scintillation spectrometric analysis
Inhibition of rat VAP-1 expressed in CHO cells using [14C]-benzylamine as substrate preincubated for 30 mins prior to substrate addition measured after 1 hr by scintillation spectrometric analysis
|
[PMID: 23664164] |
| HCT-116 | IC50 |
>100 μM
Compound: TBZ, Thiabendazole
|
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation rate after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells assessed as inhibition of cell proliferation rate after 72 hrs by MTT assay
|
[PMID: 25936258] |
| HCT-116 | IC50 |
>200 μM
Compound: X
|
Cytotoxicity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay
Cytotoxicity against Homo sapiens (human) HCT116 cells assessed as growth inhibition after 48 hr by MTT assay
|
10.1007/s00044-012-0461-8 |
| HepG2 | IC50 |
>100 μM
Compound: TBZ, Thiabendazole
|
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation rate after 72 hrs by MTT assay
Cytotoxicity against human HepG2 cells assessed as inhibition of cell proliferation rate after 72 hrs by MTT assay
|
[PMID: 25936258] |
| HL-60 | IC50 |
>20 μM
Compound: Benzimidazole
|
Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 30822712] |
| HUVEC | IC50 |
>100 μM
Compound: TBZ, Thiabendazole
|
Cytotoxicity against HUVEC assessed as inhibition of cell proliferation rate after 72 hrs by MTT assay
Cytotoxicity against HUVEC assessed as inhibition of cell proliferation rate after 72 hrs by MTT assay
|
[PMID: 25936258] |
| HUVEC | IC50 |
>250 μM
Compound: TBZ, Thiabendazole
|
Induction of vascular disruption in HUVEC after 16 hrs by inverted microscopic analysis
Induction of vascular disruption in HUVEC after 16 hrs by inverted microscopic analysis
|
[PMID: 25936258] |
| MCF7 | IC50 |
>20 μM
Compound: Benzimidazole
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 30822712] |
| SMMC-7721 | IC50 |
>20 μM
Compound: Benzimidazole
|
Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human SMMC7721 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 30822712] |
| SW480 | IC50 |
>20 μM
Compound: Benzimidazole
|
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 48 hrs by MTS assay
|
[PMID: 30822712] |
51-17-2|Rabeprazole Impurity E Reference Substance
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 51-17-2
-
性状 Solid
-
分子量 118.14
-
分子式 C7H6N2
-
Color White to yellow
-
SMILES
C12=CC=CC=C1NC=N2
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
溶剤 & 溶解度
H2O : 5 mg/mL (42.32 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
純度とドキュメンテーション
-
データシート (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
取扱説明書 (2659 KB)
参考文献
[2]. Fei F, et al. New substituted benzimidazole derivatives: a patent review (2010 - 2012). Expert Opin Ther Pat. 2013 Sep;23(9):1157-79. [Content Brief]
[3]. Wang M, et al. New substituted benzimidazole derivatives: a patent review (2013 - 2014). Expert Opin Ther Pat. 2015 May;25(5):595-612. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 8.4645 mL | 42.3227 mL | 84.6453 mL | 211.6133 mL |
| 5 mM | 1.6929 mL | 8.4645 mL | 16.9291 mL | 42.3227 mL | |
| 10 mM | 0.8465 mL | 4.2323 mL | 8.4645 mL | 21.1613 mL | |
| 15 mM | 0.5643 mL | 2.8215 mL | 5.6430 mL | 14.1076 mL | |
| 20 mM | 0.4232 mL | 2.1161 mL | 4.2323 mL | 10.5807 mL | |
| 25 mM | 0.3386 mL | 1.6929 mL | 3.3858 mL | 8.4645 mL | |
| 30 mM | 0.2822 mL | 1.4108 mL | 2.8215 mL | 7.0538 mL | |
| 40 mM | 0.2116 mL | 1.0581 mL | 2.1161 mL | 5.2903 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.